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Abstract. 
 
Platelet agonists increase the affinity state of 
integrin 
 
a
 
IIb
 
b
 
3
 
, a prerequisite for fibrinogen binding 
and platelet aggregation. This process may be triggered 
by a regulatory molecule(s) that binds to the integrin 
cytoplasmic tails, causing a structural change in the re-
ceptor. 
 
b
 
3
 
-Endonexin is a novel 111–amino acid protein 
that binds selectively to the 
 
b
 
3
 
 tail. Since 
 
b
 
3
 
-endonexin 
is present in platelets, we asked whether it can affect 
 
a
 
IIb
 
b
 
3
 
 function. When 
 
b
 
3
 
-endonexin was fused to green 
fluorescent protein (GFP) and transfected into CHO 
cells, it was found in both the cytoplasm and the nu-
cleus and could be detected on Western blots of cell ly-
sates. PAC1, a fibrinogen-mimetic mAb, was used to 
monitor 
 
a
 
IIb
 
b
 
3
 
 affinity state in transfected cells by flow 
cytometry. Cells transfected with GFP and 
 
a
 
IIb
 
b
 
3
 
 bound 
little or no PAC1. However, those transfected with 
GFP/
 
b
 
3
 
-endonexin and 
 
a
 
IIb
 
b
 
3
 
 bound PAC1 specifically 
in an energy-dependent fashion, and they underwent fi-
brinogen-dependent aggregation. GFP/
 
b
 
3
 
-endonexin 
did not affect levels of surface expression of 
 
a
 
IIb
 
b
 
3
 
 nor 
did it modulate the affinity of an 
 
a
 
IIb
 
b
 
3
 
 mutant that is 
defective in binding to 
 
b
 
3
 
-endonexin. Affinity modula-
tion of 
 
a
 
IIb
 
b
 
3
 
 by GFP/
 
b
 
3
 
-endonexin was inhibited by co-
expression of either a monomeric 
 
b
 
3
 
 cytoplasmic tail 
chimera or an activated form of H-Ras. These results 
demonstrate that 
 
b
 
3
 
-endonexin can modulate the affin-
ity state of 
 
a
 
IIb
 
b
 
3
 
 in a manner that is structurally specific 
and subject to metabolic regulation. By analogy, the ad-
hesive function of platelets may be regulated by such 
protein–protein interactions at the level of the cytoplas-
mic tails of 
 
a
 
IIb
 
b
 
3
 
.
 
I
 
ntegrins
 
 are 
 
ab
 
 heterodimers and each subunit con-
tains a relatively large extracellular domain, a mem-
brane-spanning domain, and a 20–70–amino acid cy-
toplasmic tail. They function in cell adhesion and signaling
by interacting with extracellular matrix proteins or cellular
counter-receptors on the one hand, and with intracellular
proteins on the other (8, 34, 59). The adhesive function of
many integrins is subject to rapid regulation by two pro-
cesses collectively referred to as “inside-out” signaling: (
 
a
 
)
a structural change intrinsic to the heterodimer, and (
 
b
 
)
clustering of heterodimers within the plane of the plasma
membrane. The former modulates the affinity of the
ligand–receptor interaction and thus is often referred to as
“affinity modulation.” The latter increases the valency
and, therefore, the avidity of the interaction. These two
types of regulation are not mutually exclusive, and their
relative contributions probably vary with the integrin and
the cell type (12, 20, 62, 71).
A good example of the pathophysiological significance
of rapid integrin regulation involves platelet 
 
a
 
IIb
 
b
 
3
 
. Circu-
lating platelets ordinarily do not interact with each other
or with the blood vessel wall. However, when the vessel is
damaged by trauma or disease, platelets become activated
and 
 
a
 
IIb
 
b
 
3
 
 is converted within seconds into a functional re-
ceptor for several Arg-Gly-Asp–containing ligands, in-
cluding fibrinogen and von Willebrand factor. Since ligand
binding is required for platelet aggregation, inside-out sig-
naling is a prerequisite for primary hemostasis and for for-
mation of occlusive platelet thrombi in vascular diseases
(9, 27). Affinity modulation is thought to be responsible
for the initial, reversible phase of fibrinogen binding to
platelets, while integrin clustering may be involved in sta-
bilizing the interaction (14, 52).
Studies with intact and permeabilized platelets indicate
that specific intracellular mediators promote rapid in-
creases or decreases in ligand binding to 
 
a
 
IIb
 
b
 
3
 
. Excitatory
platelet agonists, such as thrombin, increase ligand binding
by a process that involves heterotrimeric G proteins and
protein and lipid kinases (38, 61, 69, 74). On the other
hand, substances such as prostacyclin and nitric oxide,
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which stimulate protein kinase A and protein kinase G, re-
spectively, inhibit or reverse ligand binding (22, 28). In ad-
dition to intracellular mediators, the cytoplasmic tails of
 
a
 
IIb
 
b
 
3
 
 appear to participate in the regulation of fibrinogen
binding. Platelets from patients with variant forms of
Glanzmann thrombasthenia due to a deletion or mutation
in the 
 
b
 
3
 
 cytoplasmic tail fail to aggregate in response to
agonists despite near normal levels of 
 
a
 
IIb
 
b
 
3
 
 (6; Wang, R.,
D.R. Ambruso, and P.J. Newman. 1994. 
 
Blood.
 
 84:244
 
a
 
).
However, it is not clear how intracellular signals affect the
cytoplasmic tails of 
 
a
 
IIb
 
b
 
3
 
 or how changes at the level of
these tails regulate ligand binding. One hypothesis is that
specific intracellular proteins bind to the tails and promote
a structural change that is propagated across the plasma
membrane to the extracellular face of the receptor. Ac-
cordingly, recent efforts have focused on identifying pro-
teins that interact with integrin cytoplasmic tails (11).
Using a yeast two-hybrid screening strategy, we recently
discovered a novel 111–amino acid polypeptide called 
 
b
 
3
 
-
endonexin, which is capable of binding to the cytoplasmic
tail of the 
 
b
 
3
 
 integrin subunit, both in yeast and in vitro
(63). However, it fails to bind to other integrin tails, in-
cluding those of 
 
b
 
1
 
, 
 
b
 
2
 
, and 
 
a
 
IIb
 
. Since 
 
b
 
3
 
-endonexin is ex-
pressed in platelets, the present studies were carried out to
determine whether this protein can modulate the ligand-
binding function of 
 
a
 
IIb
 
b
 
3
 
. Using a CHO cell model system
to transiently express 
 
a
 
IIb
 
b
 
3
 
 and 
 
b
 
3
 
-endonexin, we now re-
port that this protein can increase the affinity state and the
adhesive function of 
 
a
 
IIb
 
b
 
3
 
. Moreover, these effects are
structurally specific and subject to metabolic regulation.
 
Materials and Methods
 
Reagents
 
Mammalian expression vectors for green fluorescent protein (GFP)
 
1
 
(pS65T-C1 and pEGFP-C1) were obtained from Clontech (Palo Alto, CA).
Monoclonal antibodies PAC1, A2A9, D57, anti-LIBS1, and anti-LIBS6
were obtained from ascites and purified as described (30). PAC1 was con-
jugated to phycoerythrin (PE) by first derivatizing it with 
 
N
 
-succinimidyl
 
S
 
-acetylthioacetate (Pierce Chemical Co., Rockford, IL). SH groups were
deprotected with hydroxylamine, and the antibody was then coupled to PE
that had been derivatized with succinimidyl 4-(
 
N
 
-maleimidomethyl)cyclo-
hexane-1-carboxylate (Pierce Chemical Co.). PE:PAC1 conjugates (1:1
mol/mol) were isolated by sizing on a Superose 6 column (Pharmacia Fine
Chemicals, Piscataway, NJ). In one experiment, PAC1 IgM
 
k
 
 was first re-
duced to the 185-kD monomer at pH 8.6 with 20 mM cysteine before con-
jugating to PE (46).
 
DNA Constructs
 
To express 
 
b
 
3
 
-endonexin as a protein fused to the carboxy terminus of
GFP, 
 
b
 
3
 
-endonexin cDNA was excised from a yeast expression vector
with XbaI and BamHI (63), and the recessed 3
 
9
 
 termini were filled in us-
ing Klenow (Boehringer Mannheim Biochemicals, Indianapolis, IN). The
GFP vectors, pS65T-C1 and pEGFP-C1, were cut with XhoI, blunt-ended
with Klenow, and ligated to 
 
b
 
3
 
-endonexin with T4 DNA ligase (Boeh-
ringer Mannheim Biochemicals). After transformation of DH5
 
a
 
, clones in
the correct orientation were selected by PCR using a sense primer in GFP
and an antisense primer in 
 
b
 
3
 
-endonexin.
Plasmid DNA encoding the cytoskeletal protein, VASP, was a gift from
Ulrich Walter and Thomas Jarchau (25) (Medizinische Universitatsklinik,
Wurzburg, Germany). The coding sequence of VASP was amplified with
Pfu polymerase (Stratagene, La Jolla, CA) using a sense primer containing
 
an XhoI site and an antisense primer with an HindIII site. The digested
PCR fragment was subcloned into XhoI- and HindIII-cut pEGFP-C1 so
that VASP would be expressed in-frame at the carboxy terminus of GFP.
Plasmid DNA encoding FRNK, an autonomously expressed carboxy-ter-
minal segment of pp125
 
FAK
 
, was a gift from Michael Schaller (University
of North Carolina, Chapel Hill, NC) (57). FRNK was amplified with Pfu
polymerase with a sense primer containing a BglII site and an antisense
primer containing an EcoRI site. The digested PCR fragment was sub-
cloned into BglII- and EcoRI-cut pEGFP-C1 so that FRNK would be ex-
pressed in-frame at the carboxy terminus of GFP.
pCDM8 expression vectors encoding wild-type 
 
a
 
IIb, 
 
b
 
3
 
, a mutant form
of 
 
b
 
3
 
 containing a single amino acid substitution (S752P), and H-Ras
(G12V) have been described (33, 49). Tac-
 
b
 
3
 
 and Tac-
 
a
 
5
 
 chimeras were in
the vector, CMV-IL2R (7). All expression plasmids were amplified in 
 
Es-
cherichia coli
 
 and purified (Plasmid Maxi Kit; Qiagen, Inc., Chatsworth,
CA). Before use in transfection experiments, each plasmid was sequenced
in the Scripps Research Institute DNA Core Facility to confirm the au-
thenticity of the coding sequences.
 
Transient Protein Expression in CHO Cells
 
cDNAs were transfected into CHO-K1 cells with Lipofectamine (GIBCO
BRL, Gaithersburg, MD). A total of 5 
 
m
 
g of plasmid DNA and 20 
 
m
 
l of
Lipofectamine solution was incubated for 10 min in 200 
 
m
 
l of DME and
then diluted with 3.8 ml of DME. Unless otherwise indicated, the amount
of DNA per transfection included 0.5 
 
m
 
g each of 
 
a
 
IIb and 
 
b
 
3
 
 and varying
amounts of the GFP plasmids to obtain equivalent degrees of GFP expres-
sion (e.g., 4 
 
m
 
g of pS65T, 4 
 
m
 
g of pS65T/
 
b
 
3
 
-endonexin, 0.02 mg of pEGFP,
0.2 mg of pEGFP/b3-endonexin, or 0.05 mg of pEGFP/VASP). When nec-
essary, an empty vector (pcDNA3; Invitrogen, San Diego, CA) was in-
cluded to equalize the amount of DNA transfected. In some experiments,
2 mg of the Tac-b3, Tac-a5, or H-Ras (G12V) plasmid was cotransfected
along with pEGFP/b3-endonexin and the plasmids for aIIb and b3. DNA/
Lipofectamine mixtures were added to CHO cells at 30–50% confluence
in a 100-mm tissue-culture plate. 6 h later, the medium was changed to
DME containing 10% FBS, 1% nonessential amino acids, 2 mM l-glutamine,
100 U/ml penicillin, and 100 mg/ml streptomycin. 48 h after transfection, the
cells were evaluated biochemically and by flow cytometry.
Evaluation of GFP/b3-Endonexin Expression in
CHO Cells
Expression of GFP/b3-endonexin fusion proteins was confirmed by immu-
noblotting. 48 h after transfection, the cells were lysed for 30 min at 48C in
a lysis buffer containing 1% Triton X-100, 0.9% NaCl, 1 mM CaCl2, 50 mM
Tris, pH 7.2, and protease inhibitors (100 U/ml aprotinin, 0.5 mM leupep-
tin, 4 mM Pefabloc) (63). After clarification of the lysate in a microfuge,
protein concentration was determined with a bicinchoninic acid reagent
(BCA; Pierce Chemical Co.). 30 mg of each sample was then electrophoresed
in 14% SDS-polyacrylamide gels under reducing conditions. After transfer
to nitrocellulose, immunoblotting was performed with a rabbit polyclonal
antibody reactive with GFP (Clontech) or rabbit antibodies reactive with
b3-endonexin (63). After the addition of affinity-purified, HRP-conju-
gated goat anti–rabbit IgG, the blots were developed for 0.1–1 min using the
enhanced chemiluminescence reaction (ECL; Amersham Corp., Arling-
ton Heights, IL).
To study the binding of GFP/b3-endonexin to the b3 integrin cytoplas-
mic tail, the 47–amino acid b3 tail was expressed in bacteria with a (His)6
tag at its amino terminus (pET His Tag System; Novagen, Inc., Madison,
WI), and then immobilized on a nickel-agarose matrix. Transiently trans-
fected CHO cells expressing equivalent amounts of GFP/b3-endonexin or
GFP were lysed in 0.4 ml of the Triton X-100 lysis buffer. After clarifica-
tion, 0.35 ml was diluted with an equal volume of lysis buffer containing
no Triton, and each sample was batch-incubated with 0.1 ml packed vol-
ume of the His-b3 tail affinity matrix for 12 h at 48C while shaking. After
washing the matrices five times with 10 vol of lysis buffer, bound proteins
were eluted into 0.7 ml of lysis buffer by addition of 1 M imidazole. Sam-
ples were electrophoresed on 12% SDS-polyacrylamide gels under reduc-
ing conditions and transferred to nitrocellulose. Immunoblotting was per-
formed with the polyclonal anti-GFP antibody.
To evaluate whether GFP/b3-endonexin could be specifically coimmu-
noprecipitated with the b3 integrin subunit from CHO cells, immunopre-
cipitation studies were carried out in the Trition X-100 lysis buffer essen-
tially as described (30). The b3 integrin subunit was immunoprecipitated
from 2-mg aliquots of cell lysate using 10 mg/ml of the murine mAb, SSA6,
1. Abbreviations used in this paper: GFP, green fluorescent protein; PE,
phycoerythrin.Kashiwagi et al. b3-Endonexin and Integrin Affinity Modulation 1435
and protein A–Sepharose (1). Control immunoprecipitations were carried
out with affinity-purified mouse IgG (Zymed Laboratories, Inc., South
San Francisco, CA) and with an isotype-matched mAb against von Wille-
brand factor, RG 7 (a gift from Zaverio Ruggeri; Scripps Research Insti-
tute, La Jolla, CA). Samples were electrophoresed on 10% SDS-polyacryl-
amide gels under reducing conditions and subsequent Western blots were
probed with the polyclonal anti-GFP antibody. To demonstrate equiva-
lent recovery of the b3 integrin subunit in the immunoprecipitates, blots
were stripped and reprobed with Ab 8035, a rabbit polyclonal antibody
specific for b3.
Evaluation of aIIbb3 Affinity State
48 h after transfection, CHO cells were resuspended at 1–2 3 106 cells per
ml in Tyrode’s buffer containing 2 mM CaCl2 and MgCl2 (49). Cells were
then incubated in the dark in 50-ml aliquots with 20 mg/ml PE-PAC1 for 30
min at room temperature. Some samples also contained an anti-b3 anti-
body (2% anti-LIBS6 ascites) that stabilizes aIIbb3 in a high affinity state
(30). Others contained an aIIbb3-selective inhibitor of ligand binding (ei-
ther 2 mM Ro 43-5054 or 10 mM Integrilin) (2, 56). Samples were then di-
luted with 0.5 ml Tyrode’s buffer containing 10 mg/ml propidium iodide
(Sigma Chemical Co., St. Louis, MO) and analyzed on a FACS®can or
FACS®Calibur flow cytometer (Becton Dickinson, San Jose, CA). In one
set of experiments, the cells were preincubated for 30 min at room tem-
perature with 4 mg/ml of 2-deoxy-d-glucose (Sigma Chemical Co.) and
0.2% sodium azide before incubation with PE-PAC1.
After electronic compensation of the FL1, FL2, and FL3 fluorescence
channels, PE-PAC1 binding (FL2) was analyzed on the gated subset of
live cells (propidium iodide–negative, FL3 channel) that were positive for
GFP expression (FL1 channel). PAC1 binding was expressed as an “acti-
vation index” calculated from median fluorescence intensity measure-
ments (49). The activation index is defined as 100 3 (Fx-Fi)/(Fm-Fi),
where Fx is PAC1 fluorescence in the absence and Fi is PAC1 fluores-
cence in the presence of Ro 43-5054 or Integrilin. Fm is PAC1 fluores-
cence in the presence of anti-LIBS6.
Fibrinogen Binding Assay
Fibrinogen binding to GFP-positive cells was determined by flow cytome-
try using biotinylated anti-LIBS1, which recognizes a fibrinogen-sensitive
epitope on the b3 subunit (19). Cells were prepared as for the PAC1 bind-
ing studies and incubated for 30 min in the dark at room temperature with
fibrinogen (250 mg/ml; Enzyme Research Laboratories, South Bend, IN),
biotin-LIBS1 (20 mg/ml), and phycoerythrin-streptavidin (4% final dilu-
tion; Molecular Probes, Inc., Eugene, OR). To calculate the activation in-
dex, some aliquots were incubated with anti-LIBS6 to induce maximal fi-
brinogen binding, while others were incubated with the function-blocking
anti-aIIbb3 antibody, A2A9, to determine nonspecific fibrinogen binding.
Cells were then diluted with Tyrode’s buffer containing 10 mg/ml propid-
ium iodide, and analyzed by flow cytometry.
CHO Cell Aggregation Assay
Fibrinogen-dependent aggregation of CHO cells was quantitated by flow
cytometry as described (16), with minor modifications. First, CHO cells
stably expressing aIIbb3 (49) were labeled with a red fluorescent tracer, hy-
droxyethidine (Polysciences Inc., Junction City, OR). Then 250 ml of these
cells (4 3 106/ml) were added to siliconized glass cuvettes containing 250 ml
of cells (2 3 106/ml) that had been transfected with GFP/b3-endonexin (or
GFP) and aIIbb3. After addition of 300 mg/ml fibrinogen, the cells were
stirred with a magnetic stir bar at 1,000 rpm for 20 min at room tempera-
ture. In some cases, the incubations with fibrinogen were also carried out
in the presence of 20 mg/ml A2A9 or 10 mM Integrilin to inhibit fibrinogen
binding. Incubations were stopped by addition of 0.25% formaldehyde,
and the samples were kept on ice for 30 min before flow cytometric detec-
tion of mixed red–green cellular aggregates.
Subcellular Localization of GFP/b3-Endonexin
48 h after transfection, CHO cells were cultured on fibrinogen-coated cov-
erslips for 2 h at 378C, and then processed and analyzed by fluorescence
microscopy for expression of GFP, aIIb, and b3 as described (32). HMEC-1
human endothelial cells, which express aVb3, were similarly cultured on fi-
brinogen-coated coverslips, and then microinjected with plasmid DNA
(0.5  mg/ml) encoding various GFP proteins (45). After 4 h at 378C, the cells
were processed and analyzed by fluorescence microscopy for expression
of GFP, aV, and b3.
Results
Expression of b3-Endonexin in CHO Cells
CHO cells provide a useful model system for characteriz-
ing the adhesive and signaling functions of ectopically ex-
pressed aIIbb3 (43, 49, 50). Therefore, b3-endonexin was
transiently coexpressed with aIIbb3 in these cells to study
its effects on the ligand-binding function of this integrin.
b3-Endonexin cDNA was fused in-frame to the 39 end of
two different versions of GFP in a mammalian expression
plasmid. One form (S65T) is red-shifted and the other
(EGFP) is both red-shifted and codon-optimized for mam-
malian expression. 48 h after transfection, expression of
recombinant proteins was assessed by Western blotting of
cell lysates. GFP/b3-endonexin was detectable using an
anti-GFP antibody, and the codon-optimized plasmid pro-
vided higher levels of protein expression for a given
amount of DNA transfected (Fig. 1). Subsequently, there-
fore, the amount of each plasmid used was adjusted to ob-
tain roughly equivalent amounts of GFP/b3-endonexin ex-
pression, and the plasmids were used interchangeably in
the following experiments. GFP/b3-endonexin was also de-
tectable with polyclonal antibodies raised against either
recombinant human b3-endonexin or a synthetic peptide
consisting of the carboxy-terminal 17 residues of the pro-
tein (Fig. 1). No hamster protein cross-reactive with these
antibodies was detected in CHO cells. These results indi-
cate that full-length GFP/b3-endonexin can be expressed
in CHO cells.
Previous studies have shown that b3-endonexin binds in
vitro to the b3 integrin subunit from detergent-solubilized
platelets and CHO cells (13, 63). To determine if b3-endo-
nexin retains its ability to bind to the b3 integrin subunit
after its fusion to GFP, lysates from CHO cells expressing
GFP/b3-endonexin were passed over an affinity matrix
containing the bacterially expressed b3 cytoplasmic tail.
GFP/b3-endonexin, but not GFP, was specifically retained
by and eluted from this affinity matrix (Fig. 2 A). More-
over, GFP/b3-endonexin and the b3 integrin subunit could
be specifically coprecipitated from CHO cell lysates (Fig. 2
B). Finally, CHO cells containing GFP/b3-endonexin were
strongly fluorescent in the FL1 channel of a flow cytometer
(see below). Thus, fusion of b3-endonexin to the carboxy
terminus of GFP abrogates neither the integrin-binding func-
tion of b3-endonexin nor the fluorescent properties of GFP.
b3-Endonexin Increases the Affinity State of
Integrin aIIbb3
48 h after cotransfection of CHO cells with expression
plasmids encoding aIIbb3 and GFP/b3-endonexin, the af-
finity state of aIIbb3 was determined by flow cytometry us-
ing a PE conjugate of the fibrinogen-mimetic mAb, PAC1.
Since transfection efficiencies varied from 15–45%, data
acquisition included only live cells positive for GFP fluo-
rescence. About 75% of these cells were also positive for
aIIbb3, as assessed by staining with an antibody specific for
the aIIbb3 complex (D57). To standardize the results of
PAC1 binding from experiment to experiment, bindingThe Journal of Cell Biology, Volume 137, 1997 1436
was expressed as an activation index calculated from me-
dian fluorescence values (49). To obtain this index, non-
specific PAC1 binding was determined in the presence of a
selective inhibitor of ligand binding to aIIbb3 (either Ro
43-5054 or Integrilin). Maximal PAC1 binding was deter-
mined in the presence of an activating anti-b3 antibody
(anti-LIBS6) (49). After subtraction of nonspecific bind-
ing, this maximal binding was assigned an activation index
of 100. Consequently, the activation index for PAC1 bind-
ing can range from 0 to 100.
Fig. 3 shows the results of a representative experiment.
PAC1 binding to CHO cells transfected with GFP/b3-
endonexin and aIIbb3 exhibited a relatively high activation
index of 44 (Fig. 3 A). In contrast, PAC1 binding to cells
transfected with GFP and aIIbb3 exhibited a lower activa-
tion index of 18 (Fig. 3 D), a value similar to that observed
previously for aIIbb3 transfectants in the absence of GFP
(31, 49). Thus, expression of b3-endonexin appears to acti-
vate aIIbb3 and increase its affinity for a cognate ligand.
This impression was confirmed by the series of experi-
ments summarized in Fig. 4. Compared with cells express-
ing GFP, those expressing GFP/b3-endonexin consistently
showed an increase in PAC1 binding, and the difference
was statistically significant (P , 0.03). In contrast, PAC1
binding to cells expressing an unrelated GFP fusion pro-
tein, GFP/VASP, was not increased despite similar levels
of recombinant protein expression. VASP was chosen be-
cause it is present in platelets and localizes to integrin-rich
focal adhesions (25). Although not shown, the PAC1 acti-
vation index for GFP/b3-endonexin cells (44 6 5) began to
approach that for cells expressing a constitutively active
form of aIIbb3 (aIIba6Ab3; 61 6 6; n 5 3) (49). Expression
of GFP/b3-endonexin or the other GFP proteins did not
affect levels of surface expression of aIIbb3, as determined
by the binding of antibody D57. All together, these results
indicate that expression of b3-endonexin can increase the
affinity state of aIIbb3.
Platelets containing aIIbb3 with a specific point mutation
in the b3 cytoplasmic tail at position 752 (S®P) fail to bind
Figure 1. Expression of GFP
and GFP/b3-endonexin in
CHO cells. CHO cells were
either mock transfected or
transfected with 4 mg of the
indicated plasmids as de-
scribed in Materials and
Methods. 48 h later, the cells
were lysed in a buffer con-
taining Triton X-100, and 30 mg
of each sample was probed
on Western blots with the in-
dicated polyclonal antibod-
ies. (Upper arrow) Position
of GFP/b3-endonexin; (lower
arrow) position of GFP. The
band in the “mock” lane
stained with anti–b3-endonexin
carboxy-terminal antibody
migrated more slowly than
GFP/b3-endonexin and was
nonspecific.
Figure 2. Interactions of GFP/b3-endonexin with the b3 integrin
cytoplasmic tail. (A) CHO cells were transfected with 4 mg of
pS65T-GFP/b3-endonexin or pS65T-GFP. 48 h later, the cells
were lysed in a Triton X-100–containing buffer, and equal vol-
umes of the lysates were batch-incubated with a His-b3 cytoplas-
mic tail affinity matrix. After extensive washing, proteins were
eluted with 1 M imidazole, and equal volumes of the indicated
fractions were transferred to nitrocellulose and probed with a
polyclonal antibody to GFP. (Upper arrow) Position of GFP/b3-
endonexin; (lower arrow) position of GFP. Previous studies of
this kind have already documented that b3-endonexin interacts
with the b3 but not the b1 cytoplasmic tail (63). (B) CHO cells ex-
pressing both aIIbb3 and GFP/b3-endonexin (1 GFP/b3-EN) or
aIIbb3 alone (2 GFP/b3-EN) were lysed in Triton X-100 lysis
buffer, and clarified lysates were immunoprecipitated either with
a monoclonal anti-b3 antibody (SSA6), an isotype control anti-
body (RG 7), or mouse IgG (mIgG). Western blotting was per-
formed initially with a polyclonal antibody to GFP and blots were
then reprobed with a polyclonal anti-b3 antibody. The first two
lanes represent 30 mg of lysate. Lys, lysate; FT, flow-through; W1,
first wash; WL, last wash; E, eluate.Kashiwagi et al. b3-Endonexin and Integrin Affinity Modulation 1437
fibrinogen or aggregate (6). Furthermore, the binding of
b3-endonexin to this mutant b3 integrin subunit is mark-
edly reduced (63). When aIIbb3 (S752P) was coexpressed
with GFP/b3-endonexin in CHO cells, no increase in
PAC1 binding was observed (Fig. 4). This suggests that b3-
endonexin modulates the affinity state of aIIbb3 in a struc-
turally specific manner.
Functional Consequences of Integrin Affinity 
Modulation by b3-Endonexin
To determine whether the changes in PAC1 binding in-
duced by GFP/b3-endonexin translate into increased bind-
ing of a physiological ligand, the binding of fibrinogen to
CHO cells was studied by flow cytometry. Bound fibrino-
gen was detected with a biotinylated mAb (anti-LIBS1)
specific for a fibrinogen-sensitive epitope on the b3 sub-
unit (19). Specific fibrinogen binding was defined as that
inhibitable by a function-blocking anti-aIIbb3 antibody,
A2A9. CHO cells expressing wild-type aIIbb3 bind little or
no fibrinogen at a saturating concentration of ligand (250
mg/ml) (48). The same was true for cells expressing GFP
and aIIbb3. However, those expressing GFP/b3-endonexin
and aIIbb3 bound increased amounts of fibrinogen (Fig. 5).
Similar results were obtained when fibrinogen binding
was measured directly with biotinylated fibrinogen (not
shown). Thus, expression of GFP/b3-endonexin can lead
to an increase in fibrinogen binding to aIIbb3.
When fibrinogen binds to activated aIIbb3 on the surface
of platelets or CHO cells under stirring conditions, the
cells aggregate (4, 16). To determine whether GFP/b3-endo-
nexin can trigger this aggregation response, CHO cells ex-
pressing GFP/b3-endonexin and aIIbb3 were mixed with
cells containing aIIbb3 and a red fluorescent tracer, hy-
droxyethidine. After stirring for 20 min in the presence of
300 mg/ml fibrinogen, the formation of mixed, red–green
cellular aggregates was monitored by flow cytometry. The
Figure 3. Effect of GFP/b3-
endonexin on PAC1 binding
to aIIbb3 in CHO cells. CHO
cells were transfected with
aIIbb3 and either GFP/b3-endo-
nexin (contour plots A, B, and
C) or GFP (plots D, E, and
F). 48 h later, binding of PE-
PAC1 (x-axis) to green fluo-
rescent–positive cells (y-axis)
was analyzed by flow cyto-
metry. Each contour plot rep-
resents  10,000 cells. Plots B
and E represent nonspecific
PAC1 binding determined in
the presence of Ro 43-5054.
Plots C and F represent max-
imal PAC1 binding in the
presence of an activating
anti-b3 antibody, anti-LIBS6.
Note that there was more
PAC1 binding to GFP/b3-
endonexin cells (plot A) than
to GFP cells (plot D), a con-
clusion supported by the cal-
culated activation indices (plot
A, activation index 5 44%;
plot D, activation index 5
18%).
Figure 4. GFP/b3-endonexin causes activation of aIIbb3 in a struc-
turally specific manner. PAC1 binding to transfected CHO cells
was analyzed by flow cytometry as described in Materials and
Methods and in the legend to Fig. 3. (Left) CHO cells were
cotransfected with wild-type aIIbb3 and either GFP (open bar),
GFP/b3-endonexin (black bar), or GFP/VASP (shaded bar). PAC1
binding was expressed as an activation index, and the data repre-
sent means 6 SEM for 15 experiments with GFP and GFP/b3-
endonexin and three experiments with GFP/VASP. (Right) CHO
cells were cotransfected with the signaling-deficient integrin mu-
tant,  aIIbb3 (S752P), and either GFP (open bar) or GFP/b3-
endonexin (black bar). Data represent the means 6 SEM of
three experiments.The Journal of Cell Biology, Volume 137, 1997 1438
bation of the cells with 10 mM cytochalasin D, an inhibitor
of actin polymerization (data not shown). Since actin poly-
merization promotes integrin clustering (12, 71), which
would be expected to influence preferentially the binding
of multivalent ligands, these results suggest that GFP/b3-
endonexin is primarily a modulator of aIIbb3 affinity rather
than avidity.
Next, GFP/b3-endonexin was studied in CHO cells ex-
pressing both aIIbb3 and a b3 cytoplasmic tail chimera con-
taining the extracellular and transmembrane domains of
the Tac subunit of the IL-2 receptor. We reasoned that the
chimera, which does not dimerize with aIIb (7, 40), would
compete intracellularly with aIIbb3 for b3-endonexin. If so,
it should prevent b3-endonexin from binding to and modu-
lating the function of aIIbb3. Indeed, expression of the Tac/
b3 chimera prevented GFP/b3-endonexin from activating
aIIbb3 (Fig. 7). In contrast, a Tac chimera containing the
structurally unrelated a5 cytoplasmic tail exhibited no such
effect. This is consistent with the idea that b3-endonexin
modulates integrin affinity through an interaction with the
b3 cytoplasmic tail.
Affinity modulation of aIIbb3 by platelet agonists re-
quires metabolic energy (68). In CHO cells, PAC1 binding
induced by GFP/b3-endonexin was not observed if the
cells were pretreated with sodium azide and 2-deoxy-d-
glucose to inhibit oxidative metabolism (Fig. 7). In this re-
spect, the effect of b3-endonexin in the CHO cell system is
similar to that of excitatory agonists in the platelet system.
In platelets, heterotrimeric GTP-binding proteins have
been implicated in affinity modulation. On the other hand,
the role of the small GTPase, H-Ras, which is also present
in these cells, has not been examined. Recently, Hughes
and co-workers found that a constitutively active form of
H-Ras (G12V) acts as a general suppressor of integrin ad-
hesive function in CHO cells (33). Similarly, we found that
the expression of H-Ras (G12V) inhibited the effects of
GFP/b3-endonexin on PAC1 binding (Fig. 7). Taken to-
gether with the energy depletion experiments, this indi-
cates that the function of GFP/b3-endonexin is subject to
metabolic regulation.
Subcellular Localization of b3-Endonexin
In order for b3-endonexin to directly influence the func-
tion of the b3 integrin cytoplasmic tail, these proteins must
be located together in the cell. To address this question,
HMEC-1 human endothelial cells, which attach and spread
on immobilized fibrinogen through aVb3, were microin-
jected with DNA encoding GFP/b3-endonexin or GFP. 4 h
later, specific green fluorescence could be observed dif-
fusely in the cytoplasm and the nucleus. The degree of
nuclear fluorescence was much greater in the case of GFP/
b3-endonexin (Fig. 8). An identical pattern of GFP/b3-
endonexin localization was observed in CHO cells that
had been allowed to spread on fibrinogen through aIIbb3
(not shown). These results are consistent with a general-
ized cytoplasmic distribution of GFP/b3-endonexin and
with a nuclear localization that may be promoted by a con-
sensus nuclear localization signal in b3-endonexin (see Dis-
cussion).
When CHO cells containing aVb3 or aIIbb3 are allowed
to spread on fibrinogen, the b3 cytoplasmic tail is neces-
Figure 5. GFP/b3-endonexin induces fibrinogen binding to aIIbb3.
48 h after transfection of CHO cells with aIIbb3 and either GFP
(open bar) or GFP/b3-endonexin (black bar), the cells were resus-
pended in Ca21- and Mg21-containing Tyrode’s buffer and incu-
bated for 30 min at room temperature in the presence of 250 mg/ml
fibrinogen. Then fibrinogen binding to the transfected cells was
assessed by flow cytometry using phycoerythrin-streptavidin and
a biotinylated anti-b3 antibody (anti-LIBS 1) sensitive to the
presence of bound fibrinogen. Specific binding was defined as
that blocked by antibody A2A9 (20 mg/ml), and it was expressed
as an activation index. Data represent the means 6 SEM of two
experiments, each performed in triplicate.
rationale for this experimental design is that if fibrinogen
first becomes bound to activated aIIbb3 on the GFP/b3-
endonexin cells, this cell-bound fibrinogen should then be
able to recruit the red fluorescent cells into mixed aggre-
gates, even though the aIIbb3 on the red fluorescent cells is
initially in a low affinity state (Fig. 6 A) (16).
In the experiment shown in Fig. 6 B, it can be seen that
GFP/b3-endonexin promoted the formation of mixed ag-
gregates (center), an effect that could be inhibited by the
function-blocking antibody, A2A9 (right), or the cyclic
peptide, Integrilin (not shown). In three such experiments,
an average of 7.0 6 1.6% of the cells expressing GFP/b3-
endonexin were engaged in red–green aggregates, com-
pared with 3.5 6 1.9% of cells expressing GFP. While this
effect may seem small, it was statistically significant (P ,
0.01). Moreover, it should be emphasized that the extent
of mixed aggregation was limited by the required use of
red fluorescent cells expressing low affinity aIIbb3. These
results indicate that affinity modulation of aIIbb3 by b3-
endonexin can cause fibrinogen-dependent cell aggrega-
tion.
Factors That Influence Integrin Activation
by b3-Endonexin
Additional experiments were conducted to clarify the mech-
anism of action of GFP/b3-endonexin. Although PAC1 is a
multimeric IgM antibody, GFP/b3-endonexin was also found
to increase the binding of a monomeric form of PAC1 ob-
tained by enzyme digestion. In addition, PAC1 binding be-
cause of GFP/b3-endonexin was not affected by preincu-Kashiwagi et al. b3-Endonexin and Integrin Affinity Modulation 1439
sary and sufficient for localization of the b3 integrins to fo-
cal adhesions (40, 72). Immunostaining of HMEC-1 cells
revealed that aV and b3 were localized both in a diffuse
pattern consistent with a generalized plasma membrane
distribution and in discrete foci characteristic of focal ad-
hesions (Fig. 9). There was no strong or consistent local-
ization of GFP/b3-endonexin to these focal adhesions, ex-
cluding the possibility that b3-endonexin might associate
tightly with the b3 cytoplasmic tail during cytoskeletal as-
sembly. However, some weak staining of b3-endonexin in
focal adhesions was observed, suggesting that a weaker or
more transient association may occur (Fig. 9, arrowheads).
No localization of GFP to focal adhesions was detected.
As a positive control, GFP was fused to FRNK, an autono-
mously expressed segment of pp125FAK that contains a fo-
cal adhesion targeting sequence (57). After microinjec-
tion, GFP/FRNK significantly localized to focal adhesions,
demonstrating that a GFP fusion protein can target to
these structures under the experimental conditions used
here (Fig. 8). Thus, GFP/b3-endonexin is not strongly or
consistently concentrated in focal adhesions.
Discussion
These studies demonstrate that: (a) in CHO cells, expres-
sion of b3-endonexin as a fusion protein with GFP is asso-
ciated with an increase in the affinity state of integrin aIIbb3.
This affinity change enables the cells to undergo fibrino-
gen-dependent aggregation. (b) Affinity modulation of
aIIbb3 by GFP/b3-endonexin is structurally specific in that
other GFP proteins (GFP; GFP/VASP) do not promote
this response. Furthermore, GFP/b3-endonexin does not
affect the function of aIIbb3 (S752P), a mutant integrin that
is defective in binding to b3-endonexin and in integrin sig-
naling. (c) Affinity modulation by b3-endonexin may be
Figure 6. GFP/b3-endonexin
causes fibrinogen-dependent
aggregation of CHO cells. A
illustrates the rationale for
this aggregation protocol,
which is discussed in the text.
In B, as detailed in Materials
and Methods, CHO cells that
had been transfected with
aIIbb3 and GFP (left) or with
aIIbb3 and GFP/b3-endonexin
(center and right) were mixed
with CHO cells that had
been stably transfected with
aIIbb3, and then stained with
the red fluorescent dye, hy-
droxyethidine. After stirring
for 20 min in the presence of
300  mg/ml fibrinogen, the
cells were fixed with formal-
dehyde, and 10,000 propid-
ium iodide–negative and
GFP-positive cells (y-axis)
were analyzed by flow cy-
tometry. (B, right) The incu-
bation with fibrinogen was
carried out in the presence of
20 mg/ml antibody A2A9 to
inhibit fibrinogen binding.
Mixed red–green cellular ag-
gregates appear to the right
of the vertical line on the
FL2 axis.
Figure 7. Factors influencing integrin activation by GFP/b3-endo-
nexin. CHO cells were transfected with aIIbb3 and either GFP or
GFP/b3-endonexin. As detailed in Materials and Methods, some
transfectants were subjected to additional treatments before de-
termination of PAC1 binding. These included (a) cotransfection
with a Tac/b3 tail chimera; (b) cotransfection with a Tac/a5 tail chi-
mera; (c) cotransfection with a constitutively active form of H-Ras
(G12V); or (d) energy depletion by preincubation for 30 min with
0.2% sodium azide and 4 mg/ml 2-deoxy-d-glucose. Data are the
means 6 SEM of three experiments.The Journal of Cell Biology, Volume 137, 1997 1440
the consequence of its direct interaction with aIIbb3 since it
is prevented by coexpression of a Tac-b3 cytoplasmic tail
chimera. (d) The effect of b3-endonexin on aIIbb3 may be
subject to metabolic regulation since it is not observed if
cellular energy is depleted or if the cells are cotransfected
with an activated form of H-Ras. (e) GFP/b3-endonexin is
found in both the nuclear and cytoplasmic compartments
after CHO cells or HMEC-1 cells have spread on a fibrin-
ogen matrix via a b3 integrin. Taken together, these results
indicate that b3-endonexin may play a significant role in
cell adhesion and signaling through integrin aIIbb3.
We interpret the effect of GFP/b3-endonexin on PAC1
and fibrinogen binding to CHO cells to represent an ex-
ample of inside-out signaling in which b3-endonexin in-
creases the affinity of individual aIIbb3 heterodimers for
specific ligands. An alternative interpretation that b3-endo-
nexin triggers oligomerization of aIIbb3 complexes and
therefore increases receptor avidity cannot be excluded,
but it seems less likely for several reasons. First, changes
within aIIbb3 that enable the binding of RGD-containing
macromolecular ligands have been detected with both a
monovalent Fab fragment of PAC1 as well as with the na-
tive, multivalent antibody (1). This indicates that regu-
lated ligand binding to aIIbb3 is not absolutely dependent
on the valency of the ligand or, presumably, the receptor.
Second, the effect of GFP/b3-endonexin on aIIbb3 was de-
tected using either native PAC1 or a monomeric fragment
of the antibody. Third, agonist-induced clustering of b2 in-
tegrins in leukocytes and possibly aIIbb3 in platelets is fa-
cilitated by polymerization of F-actin (12, 14, 71). How-
ever, cytochalasin D, an inhibitor of actin polymerization,
had no effect on PAC1 binding induced by GFP/b3-endo-
nexin. While it is not possible to quantitate precisely the
relative contributions of affinity and avidity regulation,
based on the above considerations, we speculate that b3-endo-
nexin can regulate reversible fibrinogen binding through
affinity modulation. Other factors, including actin poly-
merization and cytoskeletal reorganization, may enhance
cell adhesion by promoting receptor clustering and irre-
versible ligand binding. Consistent with this idea, cytocha-
lasin D has been reported to inhibit primarily the later, ir-
reversible phase of fibrinogen and PAC1 binding to
platelets and CHO cells (14, 53, 54).
The present results were obtained by expressing b3-
endonexin ectopically in CHO cells. Therefore, it is possi-
ble that the function of the endogenous protein in platelets
or other cells differs quantitatively or qualitatively from
that described here. Despite this caveat, a number of ob-
servations indicate that affinity modulation may result di-
rectly from the interaction of b3-endonexin with the cyto-
plasmic tail of the b3 integrin subunit. A mutational
analysis of the b3 tail has shown that membrane-distal resi-
dues near the carboxy terminus of the tail (N756ITY) are
required for the interaction with b3-endonexin (13). Muta-
tion or deletion of these same residues also disrupts inside-
out integrin signaling in platelets and CHO cells (50;
Wang, R., D.R. Ambruso, and P.J. Newman. 1994. Blood.
84:244a). Moreover, coexpression of a b3 tail chimera, but
not an a5 tail chimera, prevented affinity modulation by
b3-endonexin, possibly because the former chimera but
not the latter could compete with aIIbb3 for binding to b3-
endonexin. Finally, when other recombinant GFP proteins
such as GFP and GFP/VASP were expressed in CHO
cells, they failed to increase aIIbb3 affinity.
Additional studies will be required to determine how
cellular energy depletion or coexpression of activated
H-Ras inhibits affinity modulation by b3-endonexin.
Nonetheless, these results imply that this function of b3-
endonexin is subject to metabolic regulation. In this con-
text, studies with platelets have suggested that serine-thre-
Figure 8. Expression of GFP, GFP/b3-endonexin, and GFP/VASP
in HMEC-1 cells. Cells were allowed to spread for 2 h on fibrinogen-
coated coverslips, and then were microinjected with the indicated
expression plasmids. 4 h later, green fluorescence was visualized in a
fluorescence microscope using an FITC filter set. Uninjected cells
were not visible under these conditions. Bar, 10 mm.Kashiwagi et al. b3-Endonexin and Integrin Affinity Modulation 1441
onine kinases (61), tyrosine kinases (23), and PI 3-kinase
(38, 74; Kovacsovics, T.J., J.H. Hartwig, L.C. Cantley, and
A. Toker. 1995. Blood. 86:454a) are involved in promoting
fibrinogen binding to aIIbb3. In contrast, compounds that
activate protein kinase A or G inhibit fibrinogen binding
(22, 28). Perhaps b3-endonexin is a direct substrate of spe-
cific kinases or phosphatases or is a target of downstream
effectors of these enzymes. For example, b3-endonexin
contains several serine and threonine residues in favorable
contexts for phosphorylation by protein kinase C and A
(63).
Suppression of integrin activation in CHO cells by acti-
vated H-Ras involves a Raf-1–initiated MAP kinase path-
way and is transcription independent (33). In contrast, an
activated variant of R-Ras was recently implicated in the
promotion of integrin-mediated cell adhesion (75). Since
the reported opposite actions of activated R-Ras and H-Ras
affect both b1 and b3 integrins, it seems unlikely that the
pathways triggered by these GTPases converge directly on
b3-endonexin. Although platelets contain both H-Ras and
R-Ras, and platelet stimulation by thrombin activates H-Ras,
the functions of these GTPases in this terminally differen-
tiated cell are unknown (64).
Based on the present results, we propose that the inter-
action of b3-endonexin with the b3 cytoplasmic tail triggers
a structural change in the integrin to reconfigure the extra-
cellular face of the receptor so that it can engage fibrino-
gen. While the nature of this propagated change is un-
known, one possibility is that there is a reorientation of the
b3 subunit relative to the aIIb subunit. This is plausible
given the biophysical evidence for interactions between
the cytoplasmic tails of aIIb and b3 (24) and for agonist-
induced structural changes in the extracellular domains of
aIIbb3 in platelets (65). In a similar manner, relatively sub-
tle changes within preexisting dimers may play a role in
ligand-triggered, “outside-in” signaling across other plasma
membrane receptors, including the bacterial aspartate re-
ceptor (66) and the mammalian EGF receptor (15).
A complete understanding of the proximate events in
inside-out signaling will require identification of all rele-
vant integrin-binding proteins and a more refined knowl-
edge of integrin structure. Progress is beginning to be made
in both of these areas (11, 42, 55). Several proteins have
been described that bind directly to integrin cytoplasmic
tails, at least in vitro. These include structural proteins of
the cytoskeleton, such as F-actin (specific for the a2 tail)
(36), a-actinin (b tails) (51), talin (b) (29), and filamin (b2)
(60), and potential signaling molecules, such as calreticulin
Figure 9. Subcellular localization of GFP/b3-endonexin and aVb3 in HMEC-1 cells. Cells were allowed to spread for 2 h on fibrinogen
and then were microinjected with GFP/b3-endonexin. 4 h later, the cells were fixed, stained with rhodamine-labeled antibodies to aV or
b3, and then examined by microscopy for GFP fluorescence (top) and rhodamine fluorescence (bottom). Two different cells are shown,
one in the lefthand panels, the other in the righthand panels. Arrowheads denote the occasional coalignment of GFP/b3-endonexin and
aVb3 in focal adhesions. Bar, 5 mm.The Journal of Cell Biology, Volume 137, 1997 1442
(a tails) (10), pp125FAK (b) (58), integrin-linked kinase (b)
(26), and cytohesin-1 (b2) (37). Of note, the expression of
calreticulin and cytohesin-1 appears to stimulate or stabi-
lize a high affinity state of integrins a2b1 and aLb2, respec-
tively (10, 37). There is no sequence similarity between
either of these proteins and b3-endonexin. Thus, a struc-
turally diverse group of cytoplasmic tail-binding proteins
may function to regulate integrins. Some like cytohesin-1
and b3-endonexin may be restricted in their action because
of their binding specificities, while others like calreticulin,
which recognizes a conserved motif in all integrin a tails,
may be less specific.
While not relevant to platelets, the localization of b3-
endonexin to the cytoplasm and nucleus of HMEC-1 and
CHO cells suggests that this protein may have more than one
function. The nuclear localization may be explained, in
part, by the presence of a consensus nuclear localization
signal in b3-endonexin (K62RKK) (35, 63). Interestingly,
several proteins implicated in cell adhesion and adhesive
signaling, including ZO-1, b-catenin, zyxin, c-Abl, and
HEF1, either exhibit cytoplasmic and nuclear localization or
shuttle between the cytoplasm and the nucleus depending
on the adhesive state of the cell (Nix, D.A., and M.C. Beck-
erle. 1995. Mol. Biol. Cell. 6:366a; 3, 21, 41, 44). The identi-
fication of other proteins that can bind to b3-endonexin
should help to explain its pattern of subcellular localization.
Focal adhesions are dynamic structures containing inte-
grins, cytoskeletal elements, and signaling molecules that
form on the basal surfaces of many types of cells in culture
and in platelets during spreading on fibrinogen (47). These
macromolecular assemblies may function to optimize trac-
tion during cell motility and to promote information flow
from the extracellular matrix to the nucleus (5, 17, 18).
The lack of consistent and strong localization of b3-endo-
nexin to b3-rich focal adhesions suggests that it may inter-
act most strongly with the b3 cytoplasmic tail while cells are
in suspension or are in the early phases of adhesion. Thus,
it is attractive to speculate that b3-endonexin may partici-
pate in integrin activation but may dissociate at later times
to permit cytoskeletal interactions with the integrin tails.
These studies provide the first clues about the functions
of b3-endonexin, but they leave several questions unan-
swered. Does b3-endonexin influence outside-in signaling
events, such as protein tyrosine phosphorylation (8)? Is b3-
endonexin subject to posttranslational modifications in
vivo, and does this affect its subcellular localization or
function? Does b3-endonexin modulate the adhesive func-
tion of aVb3, which like aIIbb3 appears to be subject to rapid
regulation in some cell types (67, 73)? Does b3-endonexin
regulate aIIbb3 in platelets?
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